Head-to-head Comparison of [18F]F-PSMA-N5 With [68Ga]Ga-PSMA-11 PET/CT in PCa Diagnosis, Recurrence, and Metastasis

Launched by ANHUI PROVINCIAL HOSPITAL · Jun 12, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new imaging agent called [18F]F-PSMA-N5 to see how well it works for diagnosing prostate cancer, checking for recurrence, and finding any spread of the disease. Researchers want to compare this new agent with an existing one, [68Ga]Ga-PSMA-11, to understand which is better at providing clear images of prostate cancer in the body. The trial is currently recruiting male participants aged 18 to 90 who have been diagnosed with prostate cancer or are suspected of having a recurrence after treatment.

If you decide to participate, you'll undergo imaging tests using both agents within a two-week period. You'll need to provide some medical history, including MRI images and PSA levels, and be willing to have a biopsy if necessary. It's important to note that there are some conditions that might prevent you from joining, such as certain health issues or if you have other cancers. Overall, this trial aims to improve the way prostate cancer is diagnosed and monitored, which could lead to better outcomes for patients.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • Aged from 18 to 90 years old;
• • Complete MRI images and clinical data (such as PSA level, Gleason grade, etc.);
• • Prostate cancer detected by PSA or imaging examination, or clinically suspected recurrence after standardized treatment;
• • simultaneous \[18F\]F-PSMA-N5 and \[68Ga\]Ga-PSMA-11 examinations within two weeks;
• • Willing to undergo surgery or needle biopsy for pathological examination after examination, or confirmed as prostate cancer by histopathology before or after treatment;
• • Sign informed consent.
• Exclusion Criteria:
• • Patients who cannot cooperate with the examination;
• • Concurrent malignant tumors;
• • Previous alcohol allergy;
• • Patients with liver and kidney dysfunction;
• • Other circumstances deemed by the investigator to be inappropriate for trial participation.